| Drug / Therapy | A Relative Bioavailability and Bioequivalence Study of Varegacestat in Healthy Participants |
| Indication | — |
| Decision Type | Phase 1 |
| Trial Phase | Phase 1 |
| ClinicalTrials.gov | NCT07610005 |
Immunome, Inc. (IMNM) operates in the Immunology sector. The current BTS Score is 45 (Grade: D).
Biotech companies frequently raise capital through secondary offerings, ATM programs, and convertible notes. Before or after major FDA decisions, dilution events are common. Understanding a company's dilution history is critical for managing risk around catalyst dates.
The Phase 1 date for A Relative Bioavailability and Bioequivalence Study of Varegacestat in Healthy Participants by Immunome, Inc. (IMNM) is scheduled for June 1, 2026. This is the target date for the FDA to make a decision on this application.
A Relative Bioavailability and Bioequivalence Study of Varegacestat in Healthy Participants is being developed by Immunome, Inc. for the treatment of its target indication. It is currently in Phase 1 clinical trials.
If A Relative Bioavailability and Bioequivalence Study of Varegacestat in Healthy Participants receives FDA approval, Immunome, Inc. (IMNM) would be able to market the drug in the United States for its target indication. This typically leads to significant stock price movement for biotech companies. Investors should monitor the Phase 1 date closely.
Biotech companies often raise capital through share offerings, which can dilute existing shareholders. You can check the current dilution risk for IMNM on DilutionWatch at dilutionwatch.com/stock/IMNM.html.
You can view the full BiotechSigns company profile for Immunome, Inc. (IMNM) at biotechsign.com/app/company/IMNM, which includes the BTS Score, signal history, clinical trial data, and insider trading activity.
This page is for informational purposes only and does not constitute investment advice. FDA decision dates are subject to change. Clinical trial outcomes are inherently uncertain. Biotech stocks are highly volatile — past performance does not guarantee future results. Always consult a qualified financial advisor before making investment decisions. BiotechSigns is not a registered investment advisor.